spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  telithromycin 

 HSMN NewsFeed - 21 Apr 2014
Spectrum Pharmaceuticals Promotes and Appoints Joseph Turgeon as President and Chief Operating Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 12 Dec 2013
VIVUS Announces License and Commercialization Agreement With Sanofi for Avanafil in Africa, Middle East, Turkey and CIS/Russia
Biopharmaceuticals Licensing
 HSMN NewsFeed - 3 Sep 2013
Spectrum Pharmaceuticals Launches Marqibo(R) (vinCRIStine sulfate LIPOSOME injection) and Ships First Commercial Orders
Biopharmaceuticals Oncology Product Launch
 HSMN NewsFeed - 26 Jun 2013
VIVUS Announces SPEDRA (avanafil) Approval in Europe
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 19 Jun 2013
AstraZeneca and Bristol-Myers Squibb Announce Top Line Results for SAVOR-TIMI-53 Cardiovascular Outcomes Trial of Onglyza(R) (saxagliptin)
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 19 Nov 2012
ZYTIGA(R) Receives Positive Regulatory Recommendation in the European Union for Treatment of Metastatic Castration-Resistant Prostate Cancer before Chemotherapy
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 21 Sep 2012
Cialis(R) (tadalafil) Tablets Recommended for Approval for the Treatment of the Signs and Symptoms of Benign Prostatic Hyperplasia in the European Union
Biopharmaceuticals Urology Regulatory
 HSMN NewsFeed - 7 Feb 2012
New Study Evaluates Cialis(R) in parallel with Tamsulosin in Men with Signs and Symptoms Suggestive of Benign Prostatic Hyperplasia
Biopharmaceuticals Urology
 HSMN NewsFeed - 25 Jan 2012
New FDA Approved Labeling For VYTORIN(R) (Ezetimibe/Simvastatin) Includes Results From the Study of Heart and Renal Protection (SHARP) in Patients With Moderate to Severe Chronic Kidney Disease
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 9 Mar 2010
Bristol-Myers Squibb and AstraZeneca Announce the Commencement of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus Trial (SAVOR-TIMI 53)
Biopharmaceuticals Cardiology Endocrinology
 HSMN NewsFeed - 26 May 2009
FDA Grants Full Approval for SPRYCEL (dasatinib) for the Treatment of Adults with Chronic Myeloid Leukemia Who Are Resistant or Intolerant to Prior Therapies Including Gleevec*
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Nov 2007
FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
Biopharmaceuticals FDA Oncology
 HSMN NewsFeed - 12 Feb 2007
sanofi-aventis Announces Update to U.S. Prescribing Information for Ketek(R) (Telithromycin)
Biopharmaceuticals FDA
 HSMN NewsFeed - 26 Dec 2006
Faropenem Phase III Clinical Trial Stopped to Consider Exclusion of Ketek Comparator
Biopharmaceuticals
 HSMN NewsFeed - 4 Oct 2006
Important safety information about KETEK (telithromycin)
Biopharmaceuticals
 HSMN NewsFeed - 29 Jun 2006
sanofi-aventis Announces Update to Ketek(R) (Telithromycin) U.S. Prescribing Information
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 Jun 2006
FDA Approves SPRYCEL(TM) (dasatinib) With Two Indications
Biopharmaceuticals Oncology FDA
Return to NewsFeed  

 Additional items found! 5

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 5 additional stories matching:
telithromycin
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.